Arcutis Biotherapeutics (ARQT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.11
- Estimate
- $0.05
- Surprise
- +120.0%
- Revenue (period 2026-06-30)
- $129.9M
- Score at report (before → after)
- 6.3 → 6.6/10
Revenue source: xbrl.
How the report landed
Arcutis Biotherapeutics (ARQT) beat the $0.05 estimate with adjusted EPS of $0.11 — a large 120.0% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.3/10) to Hold at 6.6/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ARQT Sell at 6.4/10.
3 of the last 4 quarters beat the estimate; this quarter's +120.0% surprise compares with a +68.8% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Product: ZORYVE franchise
- Concentration risk — Supplier: AstraZeneca
- Thin upside margin: 7.8%
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $31.59
- Price target
- $34.04
- Stop
- $29.38
- Upside to target
- +7.8%
- Reward-to-risk
- 0.5:1
The stock trades at 143.0× trailing but 23.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 72 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
ARQT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.95B
- P/E (fwd)
- 23.5
- P/E (ttm)
- 143.0
- 52-week range
- $19.30–$33.30
- Off 52-week high
- 5.1%
- RSI (14)
- 72
- Volume vs avg
- 0.17×
- Score today
- 6.4/10